A RANDOMIZED PHASE 2 STUDY OF ERLOTINIB PLUS PEMETREXED VS ERLOTINIB OR PEMETREXED ALONE AS SECOND-LINE TREATMENT FOR NEVER-SMOKER PATIENTS WITH NON-SQUAMOUS ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Lee, D. H. [1 ]
Lee, J. S. [1 ]
Kim, S. W. [1 ]
Rodrigues Pereira, J. [2 ]
Han, B. [3 ]
Song, X. Q. [4 ]
Wang, J. [5 ]
Kim, H-K. [6 ]
Sahoo, T. P. [7 ]
Digumarti, R. [8 ]
Wang, X. [9 ]
Altug, S. [10 ]
Orlando, M. [11 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
[2] Grp Assistencia Med, Sao Paulo, Brazil
[3] Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Peoples R China
[5] Beijing Tumor Hosp, Beijing, Peoples R China
[6] St Vincent Hosp, Suwon, South Korea
[7] Chirayu Med Coll & Hosp, Bhopal, India
[8] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[9] Eli Lilly & Co, Shanghai, Peoples R China
[10] Eli Lilly & Co, Istanbul, Turkey
[11] Eli Lilly & Co, Buenos Aires, DF, Argentina
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [1] A randomised phase II study of pemetrexed versus pemetrexed plus erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
    Dittrich, Christian
    Papai-Szekely, Zsolt
    Vinolas, Nuria
    Sederholm, Christer
    Hartmann, Joerg T.
    Behringer, Dirk
    Kazeem, Gbenga
    Desaiah, Durisala
    Leschinger, Monika I.
    von Pawel, Joachim
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) : 1571 - 1580
  • [2] Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
    Lee, Dae Ho
    Lee, Jung Shin
    Kim, Sang-We
    Rodrigues-Pereira, Jose
    Han, Baohui
    Song, Xiang-Qun
    Wang, Jie
    Kim, Hoon-Kyo
    Sahoo, Tarini Prasad
    Digumarti, Raghunadharao
    Wang, Xin
    Altug, Sedat
    Orlando, Mauro
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3111 - 3121
  • [3] ERLOTINIB (ERL) VERSUS PEMETREXED (MTA) AS SECOND-LINE TREATMENT FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): EFFICACY AND SAFETY DATA
    Zugazagoitia, J.
    Puente, J.
    Hernandez, S.
    Gonzalez-Larriba, J. L.
    Sanz, J.
    Manzano, A.
    Diaz-Rubio, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 438 - 439
  • [4] A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC
    Von Pawel, J.
    Papai-Szekely, Z.
    Vinolas, N.
    Sederholm, C.
    Klima, M.
    Desaiah, D.
    Leschinger, M. I.
    Dittrich, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Sakamori, Yuichi
    Nagai, Hiroki
    Ozasa, Hiroaki
    Kaneda, Toshihiko
    Yoshioka, Hiroshige
    Nakagawa, Hiroaki
    Tomii, Keisuke
    Okada, Asuka
    Yoshimura, Kenichi
    Hirabayashi, Masataka
    Hirai, Toyohiro
    [J]. ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
  • [6] Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice
    Zugazagoitia, J.
    Puente, J.
    Gonzalez-Larriba, J. L.
    Manzano, A.
    Sotelo, M.
    Hernandez, S.
    Sanz, J.
    Perez, P.
    Diaz-Rubio, E.
    [J]. ONCOLOGY, 2013, 84 (05) : 255 - 264
  • [7] Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase ll Trial
    Lee, Dae Ho
    Lee, Jung Shin
    Wang, Jie
    Hsia, Te-Chun
    Wang, Xin
    Kim, Jongseok
    Orlando, Mauro
    [J]. CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 616 - 629
  • [8] EFFICACY AND SAFETY OF PEMETREXED AS SECOND-LINE TREATMENT IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS
    Passaro, A.
    Pochesci, A.
    Palleschi, M.
    Pellegrino, A.
    Fabbri, M. A.
    Urbano, F.
    Gentile, V.
    Manai, C.
    Pavese, I.
    Cortesi, E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S70 - S70
  • [9] Multi-center randomized phase II trial of pemetrexed plus oxaliplatin or pemetrexed alone as the second line treatment for stage IV non-squamous non-small cell lung cancer
    Gong, Y.
    Ren, L.
    Huang, M.
    Li, L.
    Peng, F.
    Hou, M.
    Li, W.
    Jia, Y.
    Yang, H.
    Lu, Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S828 - S828
  • [10] Pharmacodynamic separation (PDS) of pemetrexed and erlotinib versus pemetrexed monotherapy as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): first-stage analysis of a randomized phase II study
    Li, Tianhong
    Gucalp, Rasim
    Piperdi, Bilal
    Walsh, William, V
    Kim, Mimi
    Cohen, Bruce
    Shan, Jidong
    Mack, Philip C.
    Lara, Jr Primo N.
    Gandara, David R.
    Perez-Soler, Roman
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S304 - S305
12345